ClinicalTrials.gg
CompletedNCT02142829Updated May 22, 2014

Pain Control in Bariatric Patients: EXPAREL(R) vs. the On-Q(R) Pain Ball

A Phase 4 interventional study of EXPAREL and On-Q Pain Ball in Obesity, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-05-22.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
101
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study was conducted to compare the effectiveness of two local pain control methods in bariatric patients by assessing the amount of postoperative pain and amount of postoperative pain medications needed. This information was used to determine which local anesthetic provided the best pain control.

Read the detailed description

The investigators have previously utilized the On-Q® pain ball to obtain local control by continuous delivery of bupivacaine to pain fibers at the incision site. On-Q makes use of an implanted catheter and a continuous infusion pump that the patient carries with them typically for 48-72 hours after surgery. EXPAREL is a long-acting liposomal delivery vehicle that extends the life of bupivacaine in the surgical site for up to 72 hours. It can be injected in all trocar sites and offers another potential solution to patient pain control without the need for a catheter and the hardware needed to deliver the local anesthetic. Patient NRS (numerical rating scale) scores for postoperative pain and total medication consumed were used to assess the differences between the two treatment groups.

02

Conditions studied

  • Obesity

Keywords

  • bariatric surgery, postoperative pain
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 101 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80, male or female

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Active comparator
    EXPAREL

    EXPAREL (bupivacaine liposome injectable suspension)

    Drug: EXPAREL

  • Active comparator
    On-Q Pain Ball

    Device for delivering bupivacaine.

    Drug: On-Q Pain Ball

Interventions

  • Also known as: bupivacaine liposome injectable suspension

  • bupivacaine HCl 0.25%

    Also known as: bupivacaine

06

What researchers measure

Primary outcomes

  1. Numeric rating scale (NRS) pain intensity scores

    The NRS was from 0 = no pain and 10 = worst pain.

    Time frame: 4-6 hours postoperatively and in the mornings of postoperative Day 1 and Day 2

Secondary outcomes

  1. Postoperative opioid consumption

    Time frame: 1 week

07

Study locations

1 site
  • Bariatric Medical Institute of Texas
    San Antonio, Texas 78240, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2014
First posted
May 20, 2014
Start
Nov 2012
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Last update
May 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02142829
Responsible party
Sponsor
First posted
May 20, 2014
Start date
Nov 2012
Primary completion
Mar 2013
Completion
Mar 2013
Last update
May 22, 2014

Study contacts

Franchell Richard-Hamilton, MD
principal investigator · Bariatric Medical Institute of Texas

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liposomal Bupivacaine · Bupivacaine

Start the discussion